Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: emil who wrote (2028)	6/10/1998 7:54:00 AM
From: sds	Read Replies (1) \| Respond to of 4676

Scrambled brains..... Hey all, that looked like great results from Isis today. Could someone tell me what the comparable results were for CNTO's drug? I know I should know this, but I got a conference going on that has totally fried my cerebral cortex.... Thanks in advance. sds

To: emil who wrote (2028)	6/10/1998 9:55:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 4676

Emil: >> Is it patent $$$ related, or is it in regard to valuable information ISIS pharma has?<< My guess is as good as anyone else. Isis combinatorial chemistry and small molecule programs (DOD, BI and Genelab) probably generate class compounds which they screened against virus target beside anti-microbial target. Probably they got some good results and similar but advanced programs (target) have MRK which got interested and screened initial compound libraries from ISIP. The results are research collaboration. Regardless that this is very early step in drug development process it show that chemist/biologist who worked on oligonucleotide can do some on small molecules. MRK will have more than 10 bb extra cash ready to put in new programs/bts deal. Isis is only first one, but it is confirmation that their programs are serious one, and not a substitution for antisense. With this program Isis will learn about HCV and be able to upgrade their own small molecule/antisense programs targeting HCV. Miljenko